Recent success in treating Epstein‑Barr virus (EBV)‑associated posttransplant lymphoproliferative disorder (PTLD) using cytotoxic T‑cell (CTL) based immunotherapy has led to interest in the development of CTL‑based immunotherapy to treat other EBV‑associated malignancies, including...

Nasopharyngeal carcinoma (NPC) has a distinct geographic distribution and strong association with Epstein‑Barr virus (EBV). Recent advances in molecular investigations and bioinformatics have disclosed critical genetic and epigenetic events in NPC. In this chapter, we will focus on important...

Apoptosis is a mechanism of cell death that is pivotal for the maintenance of cellular homeostasis within the human body. Not surprisingly, mutations rendering cells resistant to apoptosis are acquired in virtually all cancers. A full understanding of such mutations is important for the...

Treatment for nasopharyngeal carcinoma (NPC) has evolved tremendously over the last decade, owing to the integration of chemotherapy into the primary radiotherapy, improvement in tumor imaging and disease monitoring, and advances in high precision radiotherapy delivery. Several randomized...

Nasopharyngeal carcinoma (NPC) is a malignant tumour of the nasopharynx that has a strong geographical distribution, with a high incidence in Southern China. It is a tumour that has had many classification schemes proposed since the early 20th century. The latest classification proposed by the...

Tumor cell population in nasopharyngeal carcinomas (NPC) is highly heterogeneous. In addition of being heavily infiltrated by nonmalignant leucocytes, malignant NPC cells can display various phenotypes in terms of epithelial maturation and viral gene expression. These various cell...

Nasopharyngeal carcinoma (NPC) is a rare tumor in most countries but is more prevalent in Southeast Asia, North Africa and Artic regions. Multiple factors participate in the etiology of NPC including Epstein‑Barr virus (EBV) activation, genetic susceptibility and exposure to environmental...

Radiation therapy (RT) remains the mainstay of treatment for NPC patients without evidence of metastases. The goal of radiation therapy is to cure patients while preserving normal tissue function. Results from randomized clinical trials support the intensification of therapy with chemotherapy...

The concept that Epstein‑Barr Virus (EBV) is one etiological factor of NPC is supported by multiple clinical and experimental observations including the consistency of the association and the demonstration of the oncogenic potential of viral products contained in most tumors. There is...

Imaging of nasopharyngeal tumors is crucial for staging, preparing and evaluating treatment and for ensuring follow‑up. Computed tomography, magnetic resonance imaging and fluorodesoxyglucose positron emission tomography are the main imaging tools. Each device is endowed with its own...

Nasopharyngeal carcinoma (NPC) is an epithelial malignant tumor which arises from the mucosa of the nasopharyngeal cavity. NPC usually presents as painless neck lumps. It can also present with nasal, aural and/or opthalmo‑neurologic symptoms. Patients in early stage of the disease are often...

Like for most human malignant diseases, it is essential to acquire biological tools for early diagnosis of small tumors, initial evaluation of tumor aggressiveness and rapid assessment of treatment efficacy. Because of the selective infection of the malignant NPC cells by the Epstein‑Barr...